PureTech Health plc (NASDAQ:PRTC) Short Interest Down 61.5% in March

PureTech Health plc (NASDAQ:PRTC - Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 9,700 shares, a drop of 61.5% from the March 15th total of 25,200 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily volume of 4,400 shares, the short-interest ratio is currently 2.2 days.

PureTech Health Trading Up 1.1 %

Shares of NASDAQ PRTC traded up $0.18 during trading on Friday, reaching $16.93. 1,302 shares of the stock were exchanged, compared to its average volume of 4,621. The business's 50-day moving average price is $17.65 and its 200 day moving average price is $19.28. PureTech Health has a twelve month low of $13.30 and a twelve month high of $32.98.

Institutional Investors Weigh In On PureTech Health

A hedge fund recently bought a new stake in PureTech Health stock. Millennium Management LLC bought a new position in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 45,264 shares of the company's stock, valued at approximately $823,000. Millennium Management LLC owned about 0.19% of PureTech Health as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.04% of the company's stock.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.